Latest Articles

An automated and cost-effective workflow in immunopeptidomics, utilizing microfluidics technology, has been created that overcomes limitations in sample preparation and could be a powerful tool for tumor antigen discovery in sparse samples.

Scientists have identified a number of biomarkers associated with progression of Type 2 diabetes to predict insulin resistance development, which could help to manage the disease and improve patient outcomes.

What does a self-driving clinical trial look like and what does it mean for the industry? Explore the ins and outs of AI in clinical development in this article.

Our knowledge of how pathological proteins like amyloid spread and become deposited throughout the brain in many major neurodegenerative diseases is now extensive. Nevertheless, our improved understanding of Alzheimer’s molecular mechanisms has yet to bridge over to effective treatments that reverse disease progress. Are we any closer to a cure?

Pressurized metered dose inhalers are the dominant form of treatment for millions of asthma sufferers. But, with the need to phase out high global warming potential propellants that are currently integral to device function, what does the future look like for pMDI use?

This article will discuss how cell models are enabling researchers to elucidate the underlying biological mechanisms of disease to support diagnostic and therapeutic development.

This article discusses how marrying microfluidics with automation can provide the necessary level of control to perform high‑throughput LNP formulation screening in a cost-effective and timely manner, and how this approach can accelerate the development of new nanomedicines.

Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

In May, news broke of the first UK baby to be born through a new type of IVF procedure, called mitochondrial replacement therapy (MRT). We speak to a mitochondria expert to learn more about the procedure and why it is ethically "controversial".

Scientists have discovered an alternative, novel source of the important anticoagulant heparin, extracted from the mucus of the giant African snail.